Business
Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments
About this update from Disc Medicine, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini.\n\n“It is my pleasure to welcome Brian to the team at this exciting time in Gemini’s history right on the heels of our debut as a public company,” said Jason Meyenburg, Chief Executive Officer of Gemini. “Brian’s deep financial experience and results-driven attitude will be invaluable to us as we continue to develop first-in-class medicines, using insights in genetics and biology, to restore regulation of the complement system in the eye and throughout the body.”\n\n“I look forward to bringing my unique perspective and industry experience to this seasoned leadership team and supporting Gemini on their path to see disease differently,” said Mr. Piekos. “With the promising safety profile demonstrated by GEM103 to date, and more trials underway, I believe Gemini is positioned for incredible value.”\n\nMr. Piekos joins Gemini from AMAG Pharmaceuticals, where he was most recently Executive Vice President, Chief Financial Officer and Treasurer. Prior to joining AMAG, he held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. Mr. Piekos began his career as a healthcare investment banker at Needham & Company and Leerink Partners, now SVB Leerink. Mr. Piekos earned his MBA from the Simon Business School at the University of Rochester. He obtained an M.S. in molecular biology from the University of Massachusetts Medical School and a B.A. in biochemistry from Ithaca College.\n\nAbout GEM103\n\nGemini’s lead program, GEM103, is a pioneering precision medicine approach, targeting trial enrichment with genetically-defined patients. GEM103 targets a genetically-defined subset of age-related macular degeneration (AMD) patients with complement dysregulation. Of the 15 million dry AMD patients, approximately 40% (or six million) have variants in the complement factor H (CFH) gene. Such loss-of-function variants are associated with increased dry AMD disease risk. GEM103 is believed to be the first ever recombinant native compl...